New prior art in Acerta Pharma's immune disease patent dismissed by EPO
MLex Summary: Acerta Pharma's patent for a polymorphic drug form was upheld by the European Patent Office Board of Appeal, despite the introduction of new prior art evidence. The board affirmed...To view the full article, register now.
Already a subscriber? Click here to view full article